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1. Introduction 
Frequency of neurodegenerative diseases increase significantly with the age. One of the 
most frightening and devastating of all neurological disorders is the dementia that occurs in 
the elderly. Dementia is a common name for progressive degenerative brain syndromes 
which affect memory, thinking, behaviour and emotions. Dementia mainly affects older 
people, although there is a growing incidence of the cases that start before the age of 65. 
After age 65, the likelihood of developing dementia roughly doubles every five years. 
Dementia affects 1 – 6% of human population over 65 years and 10 – 20% over 80 years. In 
the present, average age is increasing and the number of people over 60 years increases as 
well. Although Ageing is a physiological process, however it seems to be linked with an 
increasing risk of origin and development of several diseases including neurodegenerative 
disorders. Dementia is characterised by the loss of or decline in memory and other cognitive 
abilities. It is caused by various diseases and conditions resulting in damaging brain cells. 
Different types of dementia (Alzheimer`s disease, vascular dementia or post-stroke 
dementia, mixed dementia, dementia with Lewy bodies, Parkinson`s disease, 
frontotemporal dementia, Creutzfeld-Jacob disease, normal pressure hydrocephalus) have 
been associated with distinct symptom patterns and distinguishing microscopic brain 
abnormalities. Alzheimer's disease (AD) is the most common cause of dementia and this 
disease represents 60 – 80% of all dementia. Alzheimer's disease is age-related disease and it 
is characterized by a range of changes in brain anatomy, biochemistry, genetic, and function. 
According to Alzheimer`s disease International in 2010, there were an estimated 35.6 million 
people with dementia worldwide. This means a 10 percent increase over previous global 
dementia prevalence reported in 2005 in The Lancet. Number of people with dementia will 
be increasing to 65.7 million by 2030 and 115.4 million by 2050. 
Hallmark abnormalities of Alzheimer`s disease are deposits of the protein fragment  
ǃ-amyloid (plaques) and twisted strands of the protein tau (tangles). Protein oxidation and 
generation of protein aggregates may be caused by loss of cell function alike a decreased 
ability of old organisms to resist the physiological stresses and oxidative damage. The 
relationship between protein aggregation, oxidative damage and neurodegenerative 
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diseases is still unclear. Study of the ageing process is very important because this process is 
a cause of onset of many neurodegenerative diseases which occurrence is raising with 
increasing age. Epidemiological studies have indicated that several genetic and 
environmental risk factors are associated with AD. Neuropathological, genetic and 
molecular biologic data suggest central roles for age-related changes in the metabolism of 
amyloid precursor protein and tau protein. 
Ageing is a universal process which started with a life origin billions years ago and in the 
present we still did not find the way how to defeat our own ageing. Nobody can say when 
and where ageing is starting. Biologic, epidemiological and demographic data represent 
base for a lot of theories which try to identify a cause of ageing or to explain the ageing 
process and its consequence death. Exact mechanisms of ageing are still unclear but 
experimental evidences support a hypothesis that ageing changes are consequences of 
increasing oxidative damage of organs, tissues, cells and biomolecules. Oxidative damage is 
elevated when production of reactive oxygen species is increased compared to the 
physiological condition or a defence ability of organism against an attack of reactive oxygen 
species is decreased. Oxidation of specific proteins can play a key role in age associated 
damage. A relationship between protein aggregation, oxidative stress and 
neurodegeneration remains unclear. One of the basic problems is the analysis of 
mechanisms that are base of damage. Both localisation and kind of damage are necessary for 
understanding of neurodegeneration. Neurodegenerative diseases are connected with an 
origin of protein deposits. It assumes that protein oxidation and generation of protein 
aggregates generates a base for a loss of cell function and a reduced ability aged organisms 
to resist to physiological stress. 
2. Alzheimer’s disease 
Ageing is the main risk factor of neurodegenerative disorders such as Alzheimer`s disease 
and Parkinson`s disease. Approximately 5% of people in age 65 years have AD and the 
prevalence of this disease increases with increasing age from 19% to 30% after 75 years of 
age. Overall, 90-95% of Alzheimer`s disease represents a sporadic form and 5-10% 
represents familiar form. Alzheimer`s disease is neurodegenerative disorder characterised 
by cognitive failures, impairment of memory and by dramatic chenges in behaviour. AD 
symptoms may include:  
• loss of memory, 
• difficulty in finding the right words or understanding what people are saying, 
• difficulty in performing previously routine tasks, and activities, 
• problems with language, 
• personality and mood changes. 
AD is the most wide-spread progressive neurological disorder in men after 65 years of age 
and it becomes very serious all-society problem in consequence of increasing of average age. 
Although the cause or causes of Alzheimer’s disease are not yet known, most experts agree 
that AD, like other common chronic conditions, probably develops as a result of multiple 
factors rather than a single cause. Risk factors for AD are: 
• age, 
• gender, 
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• diabetes mellitus, 
• stroke, 
• brain injuries, 
• education, 
• alcohol and smoking. 
The greatest risk factor for Alzheimer’s disease is advancing age, but AD is not a normal 
part of ageing. There is none available effective treatment or a preventive therapy of AD 
today and a definitive diagnosis is still established post mortem through the histopatological 
analyse of patient’s brain. 
Alois Alzheimer in 1906 described neuropsychiatric disorder affecting older people 
(Alzheimer, 1907). Nowadays this disorder is called Alzheimer`s disease. He did post mortem 
analysis of 51 years old woman (Auguste D.) who suffered from progressive pre-senile 
dementia (rapid loss of memory, disorientation in time and space) and she died four and 
half years after beginning of the disease. Alois Alzheimer observed brain atrophy with 
obvious neurofibrillar pathology and unusual deposits. For Alzheimer`s disease many 
neurochemical and pathological changes are characteristic such as gliosis, tissue atrophy 
caused by loss of synapses which is the most striking in frontal and temporal parts of brain 
cortex (fig. 1.) and by formation of two main protein clusters in extracellular and 
intracellular region of brain. Extracellular deposits or senile amyloid plaques occur the most 
frequently in neocortex. Primary they are consisting of 4 kDa, 40-42 amino acid polypeptide 
chain called amyloid ┚ peptide (Aǃ) (Glenner and Wong, 1984). Intracellular deposits 
represent neurofibrillar tangles which are generated from filaments of microtubullar 
hyperphosphorylated tau protein (Alonso et al., 2008; Grundke-Iqbal et al., 1986; Lee et al., 
1991). Tau protein is a neuronal microtubullar associated protein which is primary localized 
in axons. It is assumed that microtubullar associated proteins play a major role in conserve 
shape of cells and in a axonal transport (Buée et al., 2000). Tau induces in vivo packing and 
stabilization of cell microtubules, tightens and keeps polarity of neuronal cells. Amyloid 
plaques are example of a specific damage that is characteristic for AD while neurofibrillar 
tangles are present in different neurodegenerative pathological situations (Robert & 
Mathuranath, 2007). Created aggregates are involved in a process which leads to 
progressive degeneration and to neuron death. In the past decade, a significant body of 
evidence has pointed the attention to the amyloid processing of amyloid precurcor protein - 
“amyloid cascade”. This event is the major causative factor in AD. 
Pathogenesis of AD is complex and involves many molecular, cellular, biochemical and 
physiological pathologies. Alzheimer`s disease is a characteristic process with identifiable 
clinical state which are in a continuity with normal ageing process. It is a multifactorial 
disease and genetic as well as environmental factors are included in its pathogenesis. 
Whereas majority of AD is sporadic 5% is caused by mutations (familiar AD). There was 
observed a large loss of synapses and a neuronal death in a part of brain which is crucial for 
cognitive function including cerebral cortex, entorhinal cartex and hippocampus. Senile 
plaques created by deposits of amyloid fibres were localized in the brain. Intranerve clusters 
were estimated by electron microscopy and it was shown that they are made by paired 
spiral fibres (thin fibres, diameter 10 nm) (Kurt et al., 1997). A protein component core of 
paired spiral fibres was identified as a microtubular protein tau (Grundke-Iqbal et al., 1986). 
In the last years, two main hypothesis explaining a cause of AD development were 
proposed: hypothesis of amyloid cascade – a neurodegenerative process is a serie of events 
started by an abnormal processing of amyloid precursor protein (APP) (Hardy & Higgins, 
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1992), and hypothesis of neuronal cytoskeletal degeneration (Braak & Braak, 1991) – 
cytoskeletal changes are the  starting events of AD. 
 
 
Fig. 1. Typical changes in patients with Alzheimer`s disease 
2.1 Amyloid precursor protein 
Amyloid precursor protein (APP) is an integral type I transmembrane family of 
glycoproteins (Kang et al., 1987) and it is expressed under normal physiological condition in 
brain but its function is unknown so far. It is expressed in several kinds of cells. Gene for 
amyloid precursor protein contains 18 exons (170 kb) (Yoshikai et al., 1990). N-terminus of 
amyloid precursor protein is localized toward to extracellular domain or may be localized in 
the lumen of intracellular vesicles, such as endoplasmic reticulum, Golgi apparatus or 
intracellular endosomes (Neve & McPhie, 2000). C-terminal of APP lies in cytoplasmic 
domain (Kang et al., 1987). There are known three different forms of APP mRNA: APP695, 
APP751 and APP770 that code three isoforms of APP with 695, 751 or 770 amino acids in the 
chain. The dominant form of APP is APP with 770 amino acids. It is encoded by 18 exons, 
where exon 17 resembles the membrane-spanning domain. APP695 lacking exon 7 and exon 
8 is primarily expressed by neurons and it is the most abundant APP transcript in the brain 
(Neve et al., 1988). APP751 is lacking exon 8. A part coding of Aǃ sequence contain a 
fraction of exon 16 and exon 17 and contains 40- to 42-amino acids residues that extend from 
ecto domain to transmembrane domain of protein. N-terminal part of Aǃ originates by 
cleaving of bound between Met-Asp at the position 671-672. This process is catalysed by 
protease known as ǃ-secretase. 
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Amyloid precursor protein is sensitive to proteolysis and in vivo can be processed by two 
different pathways: amyloid and non-amyloid processing, with the contribution of three 
kinds of proteases (α-, ǃ-, Ǆ-secretase) (fig. 2.). Beta and Ǆ secretase are responsible for the 
amyloid processing and production of Aǃ40 or Aǃ42 variant with significantly higher ability 
of self-aggregate (Citron et al., 1996) and carboxyl-terminal fragments of amyloid precursor 
protein which are included in the pathogenesis of AD (Selkoe, 1999; Suh, 1997). Alpha 
secretase is responsible for non-amyloid processing of amyloid precursor protein. 
In dominant non-amyloid processing APP is cleaved first by α-secretase within Aǃ domain. 
There are produced two fragments: soluble extracellular fragment (sAPPα) and 83-residue 
COOH-terminal fragment (C83). Later C83 can be cleaved by Ǆ-secretase. It is unusual 
hydrolysis in the middle of transmembrane domain and produces small 3 kDa peptid called 
p3 and C57-59 (amyloid intracellular domain – AICD). 
Cleaving of amyloid precursor protein starts by ǃ-secretase in amyloid processing of APP 
and soluble extracellular fragment (sAPPǃ) and 99-residue COOH-terminal fragmet (C99) 
are produced. C99 is still membrane-bounded and it is substrate for Ǆ-secretase which 
releases 4 kDa amyloid ǃ peptide and AICD. Proteolysis by Ǆ-secretase is heterogeneous. It 
can be produced 40-residue peptide (Aǃ40) (main product) but also a small part of 42-residue 
COOH-terminal variant (Aǃ42). Longer and more hydrofobic Aǃ42 peptide is much more 
prone to the production of plaques than Aǃ40 (Jarret et al., 1993). It is assumed that Aǃ42 is a 
minority form of amyloid ǃ peptide and it is a main form of amyloid ǃ peptide found in 
cerebral plaques (Iwatsubo a kol., 1994). Both pathways of APP processing occurr during 
physiological conditions and therefore it is supposed that all APP fragments including Aǃ  
may be a part of current unknown normal processes. 
Alpha-secretase shows characteristics of membrane-bound metalloproteinases. Non-
amyloid processing of APP is the main pathway of APP processing which cleaves end part 
of 16 amyloid ǃ sequence generating C83 (fig. 2.) (Esch et al., 1990). Gamma-secretase 
subsequently releases a small peptide (p3) which contains C-terminus of Aǃ (fig. 2.). A 
biological importance of p3 and its role, if there is any, in the amylogenesis is still mystery. 
Sequence of Aǃ is disturbed by non-amyloid processing of APP. It is assumed that α-
secretase pathway reduces production of amyloid plaques however it has not been yet 
clearly demonstrated. In addition sAPPα, which is released by α-secretase, has trophic 
effects (Esch et al., 1990) which can act against neurotoxic effects of aggregated Aǃ (Mok et 
al., 2000). The localisation of α-secretase is unknown. However trans-Golgi (Kuentzel et al., 
1993) was suggested as a place of α-cleaving. It has been found that membrane-bound 
endoprotease on the cell surface has similar activity as α-secretase. Obscurity for α-secretase 
localisation can be explained by possibility that this enzyme can be made more by than one 
protein and enzyme. Activity of α-secretase has constitutive and inducible components. A 
constitutive activity was not identified but an inducible α-secretase activity is probably 
controlled by protein kinase C (Sinha and Lieberburg, 1999). It is shown that several 
proteases are responsible for α-secretase activity – member of ADAM (a disintegrin and 
metalloprotease) family ADAM9, ADAM10, ADAM 17/tumor necrotic factor-α (TNF-α)- 
converting enzyme (TACE) and pro-protein convertase PC7 (Brou et al., 2000; Fahrenholz & 
Postina, 2006; Lopez-Perez et al., 2001). 
Beta-site amyloid precursor protein cleaving enzyme – ┚-secretase – (BACE1, Asp2) was 
identified in 1999 as an unusual member of pepsine family of the transmembrane aspartic 
proteases (Hussain et al., 1999; Lin et al., 2000; Sinha & Lieberburg, 1999; Yan et al., 1999). 
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Fig. 2. Processing of amyloid precursor protein (APP). Non-amyloid processing of APP 
starts by α-secretase cleavage and continues by Ǆ-secretase. A soluble fragment of amyloid 
precursor protein (sAPPα), a small peptide (p3) and amyloid intracellular domain (ACID) 
are produced. Amyloid pathway of APP starts with ǃ–secretase cleavage and after that it 
continues by Ǆ–secretase. A soluble fragment of amyloid precursor protein (sAPPǃ), 
amyloid ǃ peptide and amyloid intracellular domain are generated. Amyloid ǃ peptide can 
be degradated or accumulated and therefore can be responsible for generation of amyloid 
plaques 
BACE1 has N-terminal catalytic domain containing two important aspartate residues which 
are bounded to 17-residue transmembrane domain and a short C-terminal cytoplasmic end 
(Lin et al., 2000; Yan et al., 1999). Beta-secretase activity is present in most of the cells and 
tissues (Haass et al., 1992) and the highest activity was found in the neural tissue and in the 
neural cell lines (Seubert et al., 1993). This enzyme contains four potentially N-bond 
glycosylation sites and peptide sequence at N-terminal. It is phosphorylated inside its 
cytoplasmic domain at serine residue 498 by casein kinase 1 and phosphorylation is 
happened exclusively after BACE1 maturation by pro-peptide cleaving and N-glycosylation 
(Walter et al., 2001). Gene for ǃ-secretase is localised on chromosome 11. BACE1 is an 
authentical ǃ-secretase (Hussain et al., 1999; Yan et al., 1999). Related transmembrane 
aspartyl protease (BACE2 or Asp1) (Yan et al., 1999) has similar substrate specificity (Farzan 
et al., 2000) but it is not very expressed in the brain (Bennett et al., 2000). Beta-secretase is 
expressed with APP in several regions of the brain. Recent studies demonstrate that BACE1 
levels and activity are increased in post mortem AD brains (Fukumoto et al., 2002; Harada et 
al., 2006), suggesting a role of this enzyme in AD. 
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Residual carboxyl fragments C83 and C99 which are generated after APP cleaving by α- and 
ǃ-secretase undergo proteolysis inside their domain in a cytoplasmatic membrane. It is 
regulated intramembrane proteolysis. An intracellular part goes to the nucleus where can 
influence transcription of several genes. Cleaving of C99 fragment by ┛-secretase is a final 
step in the production of Aǃ. The right position of cleaving by Ǆ-secretase is determining for 
development of AD. Gamma-secretase which catalyses secondary cleavage of APP has 
pharmacological characteristics of aspartyl protease and a specific uncertain sequential 
specificity for its substrate because many mutations in APP near Ǆ-secretase place are 
responsible for the production of Aǃ in transfected cells (Lichtenthaler et al., 1997; 
Maruyama et al., 1996). It indicates that Ǆ-secretase represents a multimer enzyme complex 
and contains at least four proteins: presenilin 1 (PS1), presenilin 2 (PS2), anterior pharynx 
defective 1 (Aph-1) and nicastrin. 
2.1.1 Gene family of amyloid precursor protein 
Amyloid precursor protein belongs to the family of genes which has three members in 
mammals: amyloid precursor protein (APP), amyloid precursor-like protein 1 (APLP1) 
and amyloid precursor-like protein 2 (APLP2). Homologues of amyloid precursor protein 
were found in Drosophila melanogaster and Caenorhabditis elegans – amyloid like protein 
(APL1) (de Strooper & Annaert, 2000). All the three proteins are type of I transmembrane 
proteins with a large extracellular domain (~ 624-700 amino acids), one transmembrane 
domain (~ 25 amino acids) and a short intracellular domain (~ 46 amino acids). Proteins 
have similar sequences but the main difference is in an absence of Aǃ sequence in two APP 
similar proteins (fig. 3). No mutations associated with AD were observed in APLP1 and 
APLP2 genes and it supports a hypothesis that Aǃ is connected with AD. 
The physiological function of APP and its homologues remains unclear. It has been 
suggested that APP plays a trophic role in neuronal cells (Neve & McPhie, 2000; Qiu et al., 
1995). Gene for amyloid precursor protein undergoes a complex alternative exon splicing 
(Selkoe, 2001a, 2001b; Tanaka et al., 1988). Other heterogenity of APP is reached by series of 
controlled posttranslational modifications such as N- and O-glycosylation, phosphorylation 
and sulfation. N-terminal domain shows a homology with Kunitz-type of serine protease 
inhibitors (KPI) (Kitaguchi et al., 1988; Ponte et al., 1988). Amyloid precursor protein may 
also participate in cell adhesion, cell proliferation, and synaptogenesis and could have 
neurotrophic and neuroprotective properties (Caillé et al., 2004; Coulson et al., 2000; Kirazov 
et al., 2001). Kamal et al. (2000) suggested that APP may serve as a membrane axonal 
transport receptor for kinesin 1. This hypothesis is interesting because several studies 
suggest that abnormal processing of APP may play a role in the pathogenesis of AD (Selkoe, 
1999; Sinha & Lieberburg, 1999). It assumes that amyloid precursor protein could modulate 
signal transduction connected with G protein (Nishimoto et al., 1993). 
Amyloid precursor protein maps to chromosome 21 in humans. Pathological mutations in 
sequence which is for amyloid ǃ peptide and for APP gene are responsible for increasing 
production of Aǃ and grow in amyloid ǃ peptide self aggregation and production of 
plaques deposits (Seubert et al., 1993). Deletion of APP gene in mouse is without any 
significant impact to their life and no higher morbidity was revealed. Nevertheless small 
changes were observed in mobility and in old animals gliosis was found (Zheng et al., 1995). 
Amyloid ǃ peptide is accumulated in some regions of brain such as cerebellum, striatum and 
thalamus and it is clearly contained in clinical signs of Alzheimer`s disease (Selkoe, 2001b). 
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Fig. 3. Functional domains in amyloid precursor protein superfamily (Adapted by Marks & 
Berg, 2008). APP – amyloid precursor protein, APLP – amyloid precursor protein-like 
protein, AICD – amyloid intracellular domain, KPI – Kunitz protease inhibitor, OX-2 – 
thymocyte MRC antigen 
2.1.2 Amyloid β peptide 
Amyloid ǃ peptide which is produced in amyloid pathway during APP processing 
preserves and accumulates whereby generates amyloid plaques in AD (fig. 4). Amyloid ǃ 
peptide contains 40 (Aǃ40) or 42 amino acids (Aǃ42) (Younkin, 1998). It is physiological 
peptide which is produced in the brain continuosly. Its level is determined by balance 
between anabolic and catabolic activities (Saido, 1998; Selkoe, 1993). Amyloid ǃ peptide is 
toxic for the cells in cell lines (Yankner et al., 1989) by different pathways and its toxicity 
correlates with the level of its aggregation. This peptide is able to influence a lot of metabolic 
pathways in brain. It is able to activate caspases, effectors of apoptosis, to affect calcium 
homeostasis by increasing intracellular calcium concentration (Mattson et al., 1993), and to 
induce neuron death. 
Neurotoxicity of Aǃ can be mediated through the ability of amyloid ǃ peptide participate in 
the production of reactive oxygen species and increased oxidative damage of biomolecules 
(fig. 4). Methionine residue 35 plays an important role in this process. Damage induced by 
Aǃ can be modulated by superoxide dismutase. Aǃ induces production of superoxide anion 
radical by stimulation of NADPH oxidase. Hydrogen peroxide arises in the presence of 
amyloid ǃ peptide through reduction of the copper and the iron. Neurotoxicity is caused 
also by binding to nicotine acetylcholine receptor, forming calcium and potassium channels 
in cell membranes, decreasing glucose transport and releasing of chemokines and cytokines.  
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Fig. 4. Relationship between amyloid ǃ peptide (Aǃ), the ageing process, oxidative damage 
and Alzheimer's disease. ROS-reactive oxygen species, PS – presenilin, APP-amyloid 
precursor protein, APOE-apolipoprotein E 
Oxidative modification of glutamate transporter and glutamate synthetase oxidation can be 
caused by Aǃ as well. In AD patients was observed mitochondrial dysfunction and reduced 
energetic metabolism in brain. The main pathway of glucose oxidation is Krebs cycle in 
mitochondria. Oxidative decarboxylation of pyruvate (product of glycolysis) is catalysed by 
pyruvate dehydrogenase complex and offers acetyl CoA initiating Krebs cycle. Pyruvate 
dehydrogenase complex is formed by three enzymes: pyruvate dehydrogenase (EC 1.2.4.1, 
E1), dihydrolipoyl transacetylase (EC 2.3.1.12, E2) and dihydrolipoyl dehydrogenase (EC 
18.1.4, E3). Rate limiting steps in Krebs cycle are reactions catalysed by pyruvate 
dehydrogenase complex and by oxoglutarate dehydrogenase complex. Oxoglutarate 
dehydrogenase complex is compact of three enzymes: oxoglutarate dehydrogenase 
(EC1.2.4.2), dihydrolipoyl succinyltransferase (EC 2.3.1.61) and dihydrolipoyl 
dehydrogenase (EC 1.8.1.4). AD patients  had decreased concentration of these enzymes. 
Calcium modulates a lot of metabolic processes including synaptic plasticity and apoptosis. 
In the pathogenesis of AD play an important role dysregulation of intracellular calcium 
signalling. It is assumed that neurodegeneration induced by Aǃ and protein tau can be 
mediated by changes in calcium homeostasis. Permanent changes in calcium homoeostasis 
are proximal reason of neurodegeneration in AD patients (Khachaturian, 1989). 
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Amyloid ǃ peptide is metabolised very quickly in the brain. Its half time is 2 hours and 10 
minutes in the plasma (Betaman et al., 2006) nevertheless it is resistant towards elimination 
(Jankowsky et al., 2005). Several proteases can participate in Aǃ conversion. However one 
dominant protease is not known today. A lots of proteases cleave monomer Aǃ in several 
positions (Eckman and Eckman, 2005; Rangan et al., 2003; Tucker et al., 2000). 
2.1.3 Amyloid β peptide degrading enzymes 
Physiological peptide - amyloid ǃ peptide is metabolised by several enzymes. Neprilysin 
(NEP; EC 3.4.24.11), endothelin-converting enzyme (ECE; EC 3.4.24.71), insulin-degrading 
enzyme (IDE; EC 3.4.24.56), and probably also plasmin (EC 3.4.21.7) which are expressed in 
the brain contribute to the proteolysis of Aǃ in the brain (Eckman et al., 2003; Iwata et al., 
2000; Shirotani et al., 2001). Decreased activity of any enzymes in consequence of genetic 
mutation or as a result of changes in gene expression and proteolytic activity during ageing 
and diseases may increase risk of AD. Insulin-degrading enzyme, neprilysin and 
endothelin-converting enzyme are not able to degrade amyloid ǃ deposits. It assumes that 
amyloid ǃ aggregates can be degraded only by plasmin (Tucker et al., 2000). Plasmin is an 
important enzyme present in blood where degrades a lot of blood plasma proteins. It is a 
serine proteinase derived from an inactive zymogen called plasminogen. 
Neprilysin 
Neprilysin (NEP) is a 90 to 110 kDa plasma membrane glycoprotein that is composed of a 
short N-terminal cytoplasmic region, a membrane-spanning domain and a large C-terminal 
extracellular, catalytic domain, which contains a HexxH zinc-binding motif (Turner et al., 
2001). Originally neprilysin was identified as a main antigen of kidney membranes thirty 
years ago. Neprilysin together with endothelin-converting enzyme 1 (ECE-1) and 
endothelin-converting enzyme 2 (ECE-2) belongs to zinc metalloproteinases, II. type of 
integral membrane peptidase – M13 family. 
Neprilysin has several roles in the central nervous system, liver, lungs, musles, and bones. It 
participates in cardiovascular regulation, inflammation, neuropeptide metabolism, cell 
migration, and proliferation (Harrison et al., 1995; Turner & Tanzawa, 1997). Neprilysin 
cleaves peptide bound of small regulatory peptides and degrades a variety of bioactive 
peptides (Turner & Tanzawa, 1997). Studies of Aǃ catabolism using inhibitors of 
metalloproteinases and neprilysin knock out mice (Iwata et al., 2000) showed that neprilysin 
is enzyme degrading amyloid ǃ peptide. Expression and activity of neprilysin is regulated 
by several factors that are related to AD, and age. 
Recently a homologue of neprilysin was discovered and named neprilysin 2 (NEP2). Unlike 
neprilysin and endothelin-converting enzyme 1, which are expressed in the central nervous 
system and periphery, NEP2 was found to be almost exclusively expressed only in selected 
population of neurons and spinal cord (Turner at al., 2004). This enzyme may also degrade 
Aǃ (Shirotani et al., 2001). 
Endothelin-converting enzyme 
Endothelin-converting enzyme (ECE) plays an important role in the metabolism of Aǃ. 
Endothelin-converting enzyme is a homologue of neprilysin and it is a zinc 
metalloproteinase. The enzyme catalyses a change of inactive molecule of big endothelin 
(bET) to a very effective vasoconstrictor endothelin 1 (ET-1) (Xu et al., 1994). Endothelin-
converting enzyme was discovered in neurons and glial cells in the brain and it is localised 
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both intra- and extra-cellularly (Barnes & Turner, 1997). The enzyme is able to hydrolyse 
some biological active peptides such as bradykinin, neurotesin, substantion P and oxidized 
chain of insulin B (Johnson et al., 1999). Ability of endothelin-converting enzyme to degrade  
amyloid ǃ peptide has been discovered in experiments with a metallopreoteinase inhibitor – 
phosphoramid and then its positive effect was verified in human brain (Funalot et al., 2004). 
Insulin-degrading enzyme 
Insulin-degrading enzyme (IDE) is a zinc metalloproteinase. It is primarily located in the 
cytosol but it is also found in peroxisomes (Seta & Roth, 1997). A fraction of IDE can be 
found in the plasma membrane (Vekrellis et al., 2000). Insulin-degrading enzyme is able to 
cleave in vitro several physiological substrates, including insulin, glucagon, atriopoetin, 
amylin, Aǃ. Insulin-degrading enzyme has physiological functions in insulin metabolism. It 
can degrade amyloid ǃ peptide and it is selective for amyloid ǃ peptide monomer (Farris et 
al., 2003; Vekrellis et al., 2000). Farris et al. (2003) and Miller at al. (2003) showed that 
endogenous levels of Aǃ40 and Aǃ42 were increased in the brain of IDE transgenic mice. 
Some post mortem analysis showed that decreased levels of insulin-degrading enzyme in 
patients with Alzheimer`s disease (Cook et al., 2003). Products that are produced by IDE 
cleaving of amyloid ǃ peptide are not toxic. 
2.2 Genetic risk factors for Alzheimer's disease 
Alzheimer`s disease is a multifactorial disease and genetic as well as environmental factors 
are included in AD pathology. In the last decades, several genes involved in AD have been 
identified. There is no single gene responsible for an origin of Alzheimer`s disease. 
Mutations in amyloid precursor protein, presinilin 1 and presinilin 2 are liable for familiar 
AD. Mutations and polymorphisms in multiple genes contribute to sporadic AD. 
2.2.1 Familiar form of Alzheimer's disease 
Familiar form of Alzheimer`s disease is responsible for 5-10% of all cases of AD. It is 
characterized by early manifestation of dementia (sometimes in patients 40 years old) 
(Rosenberg, 2000). Mutations in three genes – gene for amyloid precursor protein on 
chromosome 21q21, gene for presenilin 1 on chromosome 14q24.2 and gene for presenilin 
2 on chromosome 1q42.13 – increase production of Aǃ42 peptide and play a role in an 
autosomal dominant hereditary of Alzheimer`s disease (Goate et al., 1991; Levy-Lahad et 
al., 1995; Schellenberg et al., 1992). It is described 23 mutations of APP gene and 155 
mutations of PS1 gene and 9 mutations of PS2 gene (www.alzforum.org). In familiar form 
of AD is increased level of amyloid ǃ peptide years before any clinical symptoms of 
Alzheimer`s disease are observed. Interestingly, mutations in the tau gene are not 
associated with AD. 
Amyloid precursor protein 
Missense mutations in APP gene causing familiar form of AD are clustered around secretese 
cleavage sites. These mutations are responsible for increased production of Aǃ which can 
cumulate and form amyloid plaques. Concentration of Aǃ is increased in patients with 
Down syndrome. Most of these patients have neuritic plaques and tangles in their 40s. Gene 
for APP is located on chromosome 21 and patients with Down syndrome have trisomy 21, 
and this fact can be cause of AD development. Over 23 different APP mutations have been 
observed (Campion et al., 1999; Cruts & van Broeckhoven, 1998; de Jonghe et al., 2001). 
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Presenilins are main candidates for Ǆ-secretase and they are contained in amyloid 
processing of APP. The human PS1 and PS2 mutations are linked to early onset AD.  
Presenilin 1 occurs in a normal processing of APP. Many different PS1 mutations have been 
identified in 390 families. Mutations of presenilin 1 may be responsible for missing cleaving 
of APP and production of Aǃ42 the most aggressive variant for generation of amyloid 
plaques in the human brain (Xia et al., 1997). Moreover presenilin 1 acts together with 
glycogen synthase kinase (GSK3b). Glycogen synthase kinase is one of the critical protein 
kinases included in tau phosphorylation. In some cases of familiar Alzheimer`s Disease 
mutations of presenilin 1 cause an unusual interaction of PS1 with GSK3b and it can lead to 
increased hyperphosphorylation of tau protein and this form of tau protein then does not 
play its physiological roles (Takashima et al., 1998). Mutations in PS2 are a much rarer than 
in PS1 mutations. PS2 mutations have been already described in 6 families. 
2.2.2 Sporadic form of Alzheimer's disease 
Despite numerous efforts, our knowledge of the heredity of AD remains incomplete. No 
consensus exists about the involvement of gene polymorphisms in risk of AD sporadic form. 
Genes for alfa-2-macroglobulins (Blacker et al., 1998), apolipoprotein E (ApoE ε4 variant) 
(Poirier et al., 1996), component of oxoglutarate dehydrogenase complex (Ali a kol., 1994), 
glycogen synthase kinase (GSK3B) (Schaffer et al., 2008), and some mitochondrial genes may 
be involved in familiar AD as well. Genes of secretases and amyloid ǃ peptide degrading 
enzymes have been suggested as candidate genes for AD because they play a crucial role in 
a process of formation of senile plaques. The BACE1 promoter polymorphisms may 
contribute to sporadic AD (Wang & Jia, 2009). Polymorphisms in the neprilysin gene 
(Helisalmi et al., 2004), and insulin-degrading enzyme (Vepsäläinen et al., 2010) increase the 
risk for AD. Angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism 
is considered as a biomarker for AD. Insertion/deletion and other ACE polymorphisms 
have a statistically significant effect on the risk of AD (Helbecque et al., 2009; Yang & Li, 
2008; Wang et al., 2006). Oxidative damage is one of the mechanisms which results in 
stimulation of the amyloid pathway of APP processing therefore genes of antioxidant 
enzymes could present another group of candidate genes. Catalase (EC 1.11.1.6) is a 
common antioxidant enzyme found in all organisms. Catalase gene polymorphism does not 
confirm a protective role in AD patients (Capurso et al., 2008). Glutathione transferases 
(GSTs, EC 2.5.1.18) may play an important role as risk factors for AD because GSTs detoxify 
products of oxidative damage. Polymorphisms of GSTs can be therefore implicated in AD 
(Pinhel et al., 2008; Spalletta et al., 2007). 
Apolipoprotein E 
The most important genetic risk factor for sporadic AD is the ApoE gene, its ε4 allele, and is 
linked to familial late onset AD as well. ApoE is essential for a normal metabolism of 
lipoproteins, cholesterol and triacylgylcerols. Gene for ApoE is located on chomosome 
19q13.2-13.3 and consists of 4 exons and 3 introns and is approximately 3.7 kb in length. 
ApoE has three isoforms: ApoE ε2 variant, ApoE ε3 variant, and ApoE ε4 variant. ApoE ε4 
variant increased the risk of AD compared to ApoE ε2 variant, and ε3 variant (Carter, 2005; 
Fernandez & Scheibe, 2005; Poirier et al., 1993). ApoE may be connected to Aǃ production 
and to increased aggreagation of Aǃ. Polymorphism in ApoE promoter may be a risk factor 
for AD as well (Bizzarro et al., 2009). 
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Cytokines are secretory proteins that mediate intracellular communication in the immune 
system. However, they regulate a variety of processes in the central nervous system and 
may be involved in AD because neurodegeneration is accompanied by inflammation (so-
called neuroinflammation). Inflammatory mediators are overexpressed and present in AD 
lesions (Selkoe, 2001a). Polymorphims in the promoter of IL-6, IL-10, and TNFα gene were 
suggested to be a risk factors for AD (Candore et al., 2007; Gnjec et al., 2008; Vural et al., 
2009). 
Methylenetetrahydrofolate reductase 
5, 10-Methylenetetrahydrofolate reductase (MTHFR, EC 1.5.1.20) is a pivotal enzyme for 
DNA synthesis and homocysteine remethylation. Increased plasma homocysteine level is a 
risk factor for the development of AD (Seshadri et al., 2002). Two common genetic 
polymorphisms in the MTHFR gene C677T (Kang et al., 1988) and A1298T (van der Put et 
al., 1998) were discovered. MTHFR polymorphism causes decreased enzymatic activity of 
MTHFR and increased of the plasma total homocysteine level. Mutation in MTHFR is 
slightly associated with the onset of senile dementia (Nishiyama et al., 2000). Genotypes and 
haplotypes of the MTHFR have important implication for the pathogenesis of AD (Bi et al., 
2009; Dorszewska et al., 2007; Gorgone et al., 2009; Kim et al., 2008; Wakutani et al., 2004). 
The MTHFR is a component of one carbon metabolism therefore it may interact with dietary 
intake of methionine, vitamins B6, B12, and folic acid in associations with AD. 
2.2.3 Epigenetics and Alzheimer's disease 
Recent evidence has suggested that histone acetylation and DNA methylation are 
implicated in the etiology of AD. Changes in chromatin structure are a prominent 
pathological feature of neurodegenerative diseases. Gene-environment interactions underlie 
neuropsychiatric disorders and epigenetics is involved in human processes (Figure 5). 
Epigenetic mechanisms refer to the processes that modify gene expression without altering 
the genetic code itself. Important epigenetic mechanisms include covalent modifications of 
two core component of chromatin: histone proteins – posttranslational modifications: 
histone acetylation, methylation, phosphorylation and the DNA – methylation, nucleosome 
positioning, higher order chromatin remodeling, deployment of numerous classes of short 
and long non-protein-coding RNAs, RNA editing and DNA recoding. Epigenetic 
mechanisms may play a crucial role in the interplay of genetic and environmental factors in 
determining a subject's phenotype (Reichenberg at al., 2009). Epigenetics may represent a 
basic molecular genetic mechanism in the pathophysiology of AD. The most frequently 
studied epigenetic mechanisms are DNA methylation and histone modification. These 
phenomena have been recognized as important permissive and submissive factors in 
controlling the expressed genome via gene transcription. 
DNA methylation 
DNA methylation is performed by the addition of a methyl group from S-adenosyl 
methionine to CpG islands by DNA methyltransferases (Mehler, 2008). Usually are 
methylated CpG islands near promoter regions of genes and DNA methylation generally 
represses transcription and so is associated with gene silencing. DNA methylation is 
dependent on the methylation potential and is closely related to the one-carbon metabolism. 
Methylenetetrahydrofolate reductase is a key enzyme in the one-carbon metabolism. The 
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enzyme is coded by the gene MTHFR on chromosome 1 location p36.3 in humans (Goyette 
et al., 1994). 
 
 
Fig. 5. Implication of epigenetic, genetic and environmental factors to Alzheimer`s disease 
origin 
Histone modifications 
The covalent modification of histones is happened at distinct amino acid residues on their 
amino terminal fails (Felsenfeld & Groudine, 2003). Histone acetylation, methylation, 
phosphorylation, ubiquitylation are the most common histone modifications. Histone 
acetylation is linked to transcriptional activation, while deacetylation is related to  
transcriptional repression (Berger, 2007). 
Epigenetic modifications contribute to the phenotype's differences. DNA methylation was 
examined in monozygotic twins discordant for AD. In AD twin was observed decreased 
DNA methylation compared to non AD twin (Mastroeni et al., 2009). Amyloid precursor 
protein has been shown to be normally methylated, and hypomethylated with age (Tohgi at 
al., 1999) and in AD patients (West et al., 1995), which subsequently enhanced production of 
Aǃ. Hypomethylation occurs with age and Aǃ may be involved in the generation of amyloid 
ǃ peptide itself. Amyloid ǃ peptide causes global DNA hypomethylation and neprilysin 
hypermethylation, which consequently suppresses its expression in mRNA and protein 
level (Chen et al., 2009). In cell culture and in human post-mortem study, hypomethylation 
of the promoter region of PS1 was found to increase presenilin expression, and enhance 
amyloid ǃ generation (Scarpa et al., 2003, Wang et al., 2008). PS1 and BACE are expressed at 
high levels in brain cells and both genes are unmethylated in brain (Fuso et al., 2005). AD 
may be associated with an increased in histone acetylation. Altered gene transcripton in AD 
has been associated with alterations in histone acetylation profiles (Kilgore et al., 2010). 
Amyloid intracellular domain (AICD) can interact in vitro with the histone acetyltransferase 
Tip60 and co-act as a transcriptional activator (Cao & Sudhof, 2001). 
www.intechopen.com
 




Neurological diseases, including AD are very serious medical problems. More than 150 
million people suffer from neurodegenerative and neurological diseases. The average age of 
the world population is increased as a result of better knowledge, advances in diagnosis and 
treatment of various diseases. Unfortunately, age represents a key risk factor for development 
of age-related diseases, such as AD. Molecular and genetic analyses represent a new potential 
for AD studying. The role of mentioned gene polymorphisms and many others gene 
polymorphisms as risk factors for the occurrence of AD is still controversial. We still need 
new studies for clear determination gene polymorphisms which are related to AD. Moreover 
multiple genotype analyses are necessary as well because a single gene polymorphism can 
be without relationship to increased risk of AD but the combination of gene polymorphisms 
may have significant effect for AD development. Every person is unique and dementia 
affects people differently - no two people will have symptoms that develop in exactly the 
same way. An individual's personality, general health and social situation are all important 
factors in determining the impact of Alzheimer`s disease on him or her. 
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diseases. From a more technical point of view, some chapters deal with the aggregation of prion proteins in
prion diseases. An additional chapter to discuss application of stem cells. This book is suitable for different
readers: college students can use it as a textbook; researchers in academic institutions and pharmaceutical
companies can take it as updated research information; health care professionals can take it as a reference
book, even patients' families, relatives and friends can take it as a good basis to understand
neurodegenerative diseases.
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